InvestingNewsTrending Stocks

Earth Life Sciences Stock Continues To Run ($CLTS)

Earth Life Sciences (OTC Pink: CLTS, $CLTS) continues to run higher. On Monday, it added another intraday 5% increase to its recent gains, putting the stock roughly 94% on volume over 10X its recent average since the second week in June. The better news- the gain wasn’t a fluke, and it added to a total 174% rise since last month. The reason? Investors are likely taking a closer look at how its acquisition of the VIVA Health Service platform could transform nano-cap CLTS into a more prominent company faster than expected.

Consider the move a delayed reaction. It first announced the VIVA deal in Q4 of 2021. But, delayed reaction or not, investors paying attention at that time are sitting on a YTD gain of more than 179%. Still, with savvy traders knowing that volume often precedes price, more significant increases could be in the near-term crosshairs. Considering what the VIVA Health platform can do, that’s a likely proposition.

Foremost, it brings to CLTS a one-stop smart branded healthcare service platform that fits ideally in the US markets with an initial emphasis on targeting Asian communities in North America. The platform focuses on the vertical fields of skincare and foot bathing, beauty and makeup, manicures, haircuts, and traditional Chinese massages for seniors. If it sounds unique, that’s because it is.

The online ordering and offline services are designed as a matching trading platform, similar to Uber, but with its mission to match and facilitate lifestyle services. In other words, using internet information technology and big data for accurate analysis, VivaHealth integrates life service resources such as physiotherapists, foot bathers, manicurists, beauticians, barbers, and medical professionals in the service areas. Don’t shrug off the revenue-generating opportunity in CLTS’s crosshairs- it addresses an enormous market potential.

AI-Powered Solutions Drive Investor Interest

According to, CLTS targets a global healthcare sector expected to reach $10.059 trillion by the end of 2022. And the lion’s share of that market will be generated from the United States, which spends significantly more on health and self-care, per capita, than other developed nations worldwide. But the better news for CLTS and its investors is that while US patients spend trillions on health and self-care-related services, that number is expected to increase appreciably yearly.

Contributing to that growth goes well beyond the sharp increase in the aging population demographic. The markets, in dollar terms, are also getting a boost from the development of technology intended to make the healthcare industry and associated services more efficient and provide access to a variety of self-care services to millions of additional patients in need. 

So, while the upfront costs are high, the long-term intended result is to lower medical costs by integrating Content Management Systems (CMS) designed to alleviate pressure on rising across-the-board prices by streamlining sector deliverables. Pre COVID-19, national healthcare and self-care spending hit $3.8 trillion. Coming out of the COVID pandemic, that number could be a fraction of global expenses.

And that surging market for services is precisely what CLTS wants to exploit. And it can, with its VIVA USA platform designed to standardize the output of brand images, service processes, service content, and training systems. It also helps upgrade professional skills and service quality for healthcare service through an innovative, easy-to-use online and offline learning and assessment platform.

Bulls Take Charge, Speculation Is Bullish

Investors could be speculating that CLTS is starting to reap the rewards from its investment. They could be right. Remember, CLTS said it expected to have its VIVA USA available in most of the United States markets, covering hundreds of cities and towns and serving millions of users and families. An update to its Phase 1 progress is imminent.

They also said they would stay committed to providing a full range of professional services, in addition to those mentioned, particularly for millions of Asian and other families in North America. This includes hospital nursing, home care, customized nursing, companions for the elderly, confinement nannies, family nannies, babysitters, and so on. 

In other words, there was a lot of business opportunity in CLTS’s crosshairs in 2021. Now, in 2022, they could be pulling the trigger to turn its prime asset into a revenue-generating juggernaut. It’s an aggressive presumption but feasible, considering there is plenty of market dollars to go around. 

With that the case, the bullish run could and should continue. Keep in mind that CLTS is significantly better positioned today than when its shares traded at 52-week highs of $0.027, 53% higher than current prices. 

Moreover, in addition to intrinsic strength through VIVA, CLTS is also a low-priced play on the future direction of medical and self-care services. That’s a result of CLTS expanding its stake and technological interests to seize massive market opportunities inherent to personal care and case management, one of the fastest-growing portions of the multi-trillion dollar health care industry.

Indeed, CLTS is surging for a reason. And while the company isn’t one to feed the market a barrage of company updates, there could very well be one in the queue to justify the recent surge. There’s no denying that market action indicates CLTS is in play. And, as is often the case, when a stock appreciates with no news on the wires, there’s likely a supporting reason lurking somewhere in the background. For those risk-tolerant investors, trading ahead of that “reason” may be a wise and timely consideration.

Disclaimers: Hawk Point Media, Group, Llc, (HPM) and its wholly-owned asset, Level3Trading is responsible for the production and distribution of this content. Level3Trading is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by Level3Trading is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall Level3Trading be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by Level3Trading, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. Level3Trading strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, Level3Trading, its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found HPM has been compensated up to three-thousand -five-hundred-dollars by a third party to produce and syndicate content for the company featured above. Contributors reserve the right, but are not obligated to, submit articles for fact-checking prior to publication. Contributors are under no obligation to accept revisions when not factually supported. Furthermore, because contributors are compensated, readers and viewers of this content should always assume that content provided shows only the positive side of companies, and rarely, if ever, highlights the risks associated with investment. Thus, readers and viewers should accept the content as an advertorial that highlights only the best features of a company. Never take opinion, articles presented, or content provided as a sole reason to invest in any featured company. Investors must always perform their own due diligence prior to investing in any publicly traded company and understand the risks involved, including losing their entire investment.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button